MHRA Class 4 Medicines Defect Information: Liothyronine Sodium 5 & 20 micrograms Tablets (Strides Pharma UK Ltd)
MHRA Class 4 Medicines Defect Information: Liothyronine Sodium 5 & 20 micrograms Tablets (Strides Pharma UK Ltd)
Drug alert number: EL (24)A/58
Date issued: 28 November 2024
The Medicines and Health products Regulatory Agency (MHRA) has issued a class 4 medicines defect information notice for: Liothyronine Sodium 5 & 20 micrograms Tablets (Strides Pharma UK Ltd)
Company name: Strides Pharma UK Ltd
Product name: Liothyronine Sodium 20 micrograms Tablets, PL 13606/0276
SNOMED Code: 42474711000001108
| Batch Number | Expiry Date | Pack Size | First Distributed |
| EH23LIF004 | 05/2025 | 28 Tablets | 25/09/2024 |
| EH24LIF001 | 08/2026 | 28 Tablets | Not yet distributed |
Active Pharmaceutical Ingredient: liothyronine sodium
Product name: Liothyronine Sodium 5 micrograms Tablets, PL 13606/0275
SNOMED Code: 42475111000001106
| Batch Number | Expiry Date | Pack Size | First Distributed |
| EH24LIE001 | 08/2026 | 28 Tablets | Not yet distributed |
Active Pharmaceutical Ingredient: liothyronine sodium
Brief description of the problem
Strides Pharma UK Ltd has informed MHRA of an error in the patient information leaflet (PIL) for Liothyronine Sodium 20 micrograms Tablets and Liothyronine Sodium 5 micrograms Tablets. The PIL incorrectly states the product name under section 5, the PIL should state ‘How to store Liothyronine Tablets’ but is written as ‘How to store Levothyroxine Tablets’.
Advice for healthcare professionals
There is no impact on the product quality and the healthcare professionals should continue prescribing the medicine. This is a typographical error in one section of the PIL only, all other labelled information is correct.
View full alert here.
Advice for patients
Patients should continue to take medicines from these batches as prescribed by your healthcare professional. This is a typographical error in one section of the PIL only, all other labelled information is correct.
If you experience any unexpected side effects or adverse reactions, these should be reported via the MHRA Yellow Card Scheme at https://yellowcard.mhra.gov.uk.
Further Information
For medical information enquiries please contact Strides Pharma UK Ltd via email dl-drugsafety@strides.com or telephone +919844460742
For stock control enquiries please contact Strides Pharma UK Ltd via email customerservicesuk@stridespharma.co.uk or telephone 01923 255580
